• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
GTG
Click for more information
0.00% 3.9¢

GENETIC TECHNOLOGIES LIMITED - Announcements

Market Cap $5.671M  ! watchlist Created with Sketch. Add to my watchlist

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics... Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and morMore

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
GTGMarket update20/07/11
GTGSuspension from Official QuotationPRICE SENSITIVE13/07/11
GTGTrading Halt Request from Company12/07/11
GTGTrading HaltPRICE SENSITIVE12/07/11
GTGSettlement with NavigenicsPRICE SENSITIVE28/06/11
GTGLaunch of BREVAGen test in USPRICE SENSITIVE20/06/11
GTGCeasing to be a substantial holder06/06/11
GTGUS investor presentation - June 201106/06/11
GTGGTG GENE processes first BREVAGen samplePRICE SENSITIVE31/05/11
GTGShareholder newsletterPRICE SENSITIVE30/05/11
GTGAppendix 3B26/05/11
GTGFiling of further patent infringement suitPRICE SENSITIVE26/05/11
GTGResponse to ASX Price and Volume QueryPRICE SENSITIVE11/05/11
GTGNotification of relocation of share register29/04/11
GTGAppendix 4C - quarterlyPRICE SENSITIVE28/04/11
GTGGenetic Technologies secures CLIA certificationPRICE SENSITIVE27/04/11
GTGCollaboration with global pharmaceutical companyPRICE SENSITIVE20/04/11
GTGSettlement and License Agreement with ViennaLab DiagnosticsPRICE SENSITIVE14/04/11
GTGSuccessful Conclusion of First Assertion SuitPRICE SENSITIVE13/04/11
GTGSettlement and License Agreement with Orchid Cellmark, Inc.PRICE SENSITIVE11/04/11
GTGAmended Appendix 3Y on new Form24/03/11
GTGChange of Director's Interest Notice24/03/11
GTGHalf Yearly Report and AccountsPRICE SENSITIVE24/02/11
GTGExtension of forensics contractPRICE SENSITIVE09/02/11
GTGAppendix 3B07/02/11
GTGAppendix 4C - quarterlyPRICE SENSITIVE28/01/11
GTGMaiden half-year profitPRICE SENSITIVE28/01/11
GTGCeasing to be a substantial holder21/01/11
GTG +Second patent infringement law suit filedPRICE SENSITIVE20/01/11
GTG +Settlement of dispute with Sunrise MedicalPRICE SENSITIVE17/01/11
GTGInvestor presentation10/01/11
GTGResponse to ASX QueryPRICE SENSITIVE07/01/11
GTGGranting of license to QiagenPRICE SENSITIVE31/12/10
GTGSecurities Trading Policy21/12/10
GTGChange of Director's Interest Notice09/12/10
GTGSettlement of dispute with Pioneer Hi-BredPRICE SENSITIVE30/11/10
GTGResults from 2010 Annual General Meeting24/11/10
GTG2010 Annual General Meeting materials24/11/10
GTGGranting of license to Laboratoires ReunisPRICE SENSITIVE23/11/10
GTGSettlement of dispute with Innogenetics NVPRICE SENSITIVE11/11/10
GTGValidation of BREVAGen in Journal of NCIPRICE SENSITIVE28/10/10
GTGAppendix 4C - quarterlyPRICE SENSITIVE28/10/10
GTGPresentation18/10/10
GTGAnnual Report to shareholders15/10/10
GTGExpiry of options12/10/10
GTGFull Year Statutory Accounts28/09/10
GTGPreliminary Final ReportPRICE SENSITIVE30/08/10
GTGSettlement of disputePRICE SENSITIVE26/08/10
GTGGTG grants license to MonsantoPRICE SENSITIVE06/08/10
GTGAppendix 4C - quarterlyPRICE SENSITIVE28/07/10
GTGAppendix 3B13/07/10
GTGTransfer to NASDAQ Capital Market30/06/10
GTGExtension of Quest LicensePRICE SENSITIVE29/06/10
GTGAppointment of Lewis Stuart22/06/10
GTGBREVAGen data presented at ASCO 201008/06/10
GTGPatent claims upheld in full by USPTOPRICE SENSITIVE10/05/10
GTGGTG grants license to EraGen BiosciencesPRICE SENSITIVE05/05/10
GTGGTG grants non-coding license to Gen-ProbePRICE SENSITIVE03/05/10
GTGAppendix 4C - quarterlyPRICE SENSITIVE28/04/10
GTGSigned Notice of Initial Substantial Shareholder15/04/10
GTGBecoming a substantial holder14/04/10
GTGAcquisition of BREVAGenPRICE SENSITIVE14/04/10
GTGAppendix 3BPRICE SENSITIVE14/04/10
GTGInvestor update31/03/10
GTGExpiry of options02/03/10
GTGHalf Yearly Report and AccountsPRICE SENSITIVE25/02/10
GTGAssertion of intellectual property rights16/02/10
GTGAppendix 4C - quarterlyPRICE SENSITIVE29/01/10
GTGExpiry of options28/01/10
GTGAudio broadcast by CEO08/01/10
GTGResponse Genetics Distribution AgreementPRICE SENSITIVE06/01/10
GTGUS Annual Report on Form 20-F29/12/09
GTGExclusive Option AgreementPRICE SENSITIVE17/12/09
GTGCancellation of Options03/12/09
GTGFinal Director's Interest Notice25/11/09
GTGInitial Director's Interest Notice25/11/09
GTGDirector Appointment/Resignation25/11/09
GTGResults of Meeting25/11/09
GTGDirector Appointment/Resignation25/11/09
GTGMaterials for 2009 AGM25/11/09
GTGAppendix 4C - quarterlyPRICE SENSITIVE29/10/09
GTGShareholder Update26/10/09
GTGRosetta Genomics Distribution AgreementPRICE SENSITIVE23/10/09
GTGAGM Proxy Form09/10/09
GTGNotice of Annual General Meeting/Proxy Form09/10/09
GTGAnnual Report to shareholders09/10/09
GTGInitial Director's Interest Notice05/10/09
GTGDirector Appointment/Resignation05/10/09
GTGPreliminary Final ReportPRICE SENSITIVE28/08/09
GTGAppendix 4C - quarterlyPRICE SENSITIVE30/07/09
GTGUS Patent Update30/06/09
GTGExpiry of Options11/06/09
GTGWithdrawal of German nullification actionPRICE SENSITIVE10/06/09
GTGImmunAid project updatePRICE SENSITIVE09/06/09
GTGAppendix 4C - quarterlyPRICE SENSITIVE29/04/09
GTGAppointment of new CEO21/04/09
GTGExpiry of options12/03/09
GTGHalf Yearly Report and AccountsPRICE SENSITIVE26/02/09
GTGCancellation of options02/02/09
GTGAppendix 4C - quarterlyPRICE SENSITIVE29/01/09
GTGMarket update
20/07/11
GTGSuspension from Official Quotation
13/07/11PRICE SENSITIVE
GTGTrading Halt Request from Company
12/07/11
GTGTrading Halt
12/07/11PRICE SENSITIVE
GTGSettlement with Navigenics
28/06/11PRICE SENSITIVE
GTGLaunch of BREVAGen test in US
20/06/11PRICE SENSITIVE
GTGCeasing to be a substantial holder
06/06/11
GTGUS investor presentation - June 2011
06/06/11
GTGGTG GENE processes first BREVAGen sample
31/05/11PRICE SENSITIVE
GTGShareholder newsletter
30/05/11PRICE SENSITIVE
GTGAppendix 3B
26/05/11
GTGFiling of further patent infringement suit
26/05/11PRICE SENSITIVE
GTGResponse to ASX Price and Volume Query
11/05/11PRICE SENSITIVE
GTGNotification of relocation of share register
29/04/11
GTGAppendix 4C - quarterly
28/04/11PRICE SENSITIVE
GTGGenetic Technologies secures CLIA certification
27/04/11PRICE SENSITIVE
GTGCollaboration with global pharmaceutical company
20/04/11PRICE SENSITIVE
GTGSettlement and License Agreement with ViennaLab Diagnostics
14/04/11PRICE SENSITIVE
GTGSuccessful Conclusion of First Assertion Suit
13/04/11PRICE SENSITIVE
GTGSettlement and License Agreement with Orchid Cellmark, Inc.
11/04/11PRICE SENSITIVE
GTGAmended Appendix 3Y on new Form
24/03/11
GTGChange of Director's Interest Notice
24/03/11
GTGHalf Yearly Report and Accounts
24/02/11PRICE SENSITIVE
GTGExtension of forensics contract
09/02/11PRICE SENSITIVE
GTGAppendix 3B
07/02/11
GTGAppendix 4C - quarterly
28/01/11PRICE SENSITIVE
GTGMaiden half-year profit
28/01/11PRICE SENSITIVE
GTGCeasing to be a substantial holder
21/01/11
GTG +Second patent infringement law suit filed
20/01/11PRICE SENSITIVE
GTG +Settlement of dispute with Sunrise Medical
17/01/11PRICE SENSITIVE
GTGInvestor presentation
10/01/11
GTGResponse to ASX Query
07/01/11PRICE SENSITIVE
GTGGranting of license to Qiagen
31/12/10PRICE SENSITIVE
GTGSecurities Trading Policy
21/12/10
GTGChange of Director's Interest Notice
09/12/10
GTGSettlement of dispute with Pioneer Hi-Bred
30/11/10PRICE SENSITIVE
GTGResults from 2010 Annual General Meeting
24/11/10
GTG2010 Annual General Meeting materials
24/11/10
GTGGranting of license to Laboratoires Reunis
23/11/10PRICE SENSITIVE
GTGSettlement of dispute with Innogenetics NV
11/11/10PRICE SENSITIVE
GTGValidation of BREVAGen in Journal of NCI
28/10/10PRICE SENSITIVE
GTGAppendix 4C - quarterly
28/10/10PRICE SENSITIVE
GTGPresentation
18/10/10
GTGAnnual Report to shareholders
15/10/10
GTGExpiry of options
12/10/10
GTGFull Year Statutory Accounts
28/09/10
GTGPreliminary Final Report
30/08/10PRICE SENSITIVE
GTGSettlement of dispute
26/08/10PRICE SENSITIVE
GTGGTG grants license to Monsanto
06/08/10PRICE SENSITIVE
GTGAppendix 4C - quarterly
28/07/10PRICE SENSITIVE
GTGAppendix 3B
13/07/10
GTGTransfer to NASDAQ Capital Market
30/06/10
GTGExtension of Quest License
29/06/10PRICE SENSITIVE
GTGAppointment of Lewis Stuart
22/06/10
GTGBREVAGen data presented at ASCO 2010
08/06/10
GTGPatent claims upheld in full by USPTO
10/05/10PRICE SENSITIVE
GTGGTG grants license to EraGen Biosciences
05/05/10PRICE SENSITIVE
GTGGTG grants non-coding license to Gen-Probe
03/05/10PRICE SENSITIVE
GTGAppendix 4C - quarterly
28/04/10PRICE SENSITIVE
GTGSigned Notice of Initial Substantial Shareholder
15/04/10
GTGBecoming a substantial holder
14/04/10
GTGAcquisition of BREVAGen
14/04/10PRICE SENSITIVE
GTGAppendix 3B
14/04/10PRICE SENSITIVE
GTGInvestor update
31/03/10
GTGExpiry of options
02/03/10
GTGHalf Yearly Report and Accounts
25/02/10PRICE SENSITIVE
GTGAssertion of intellectual property rights
16/02/10
GTGAppendix 4C - quarterly
29/01/10PRICE SENSITIVE
GTGExpiry of options
28/01/10
GTGAudio broadcast by CEO
08/01/10
GTGResponse Genetics Distribution Agreement
06/01/10PRICE SENSITIVE
GTGUS Annual Report on Form 20-F
29/12/09
GTGExclusive Option Agreement
17/12/09PRICE SENSITIVE
GTGCancellation of Options
03/12/09
GTGFinal Director's Interest Notice
25/11/09
GTGInitial Director's Interest Notice
25/11/09
GTGDirector Appointment/Resignation
25/11/09
GTGResults of Meeting
25/11/09
GTGDirector Appointment/Resignation
25/11/09
GTGMaterials for 2009 AGM
25/11/09
GTGAppendix 4C - quarterly
29/10/09PRICE SENSITIVE
GTGShareholder Update
26/10/09
GTGRosetta Genomics Distribution Agreement
23/10/09PRICE SENSITIVE
GTGAGM Proxy Form
09/10/09
GTGNotice of Annual General Meeting/Proxy Form
09/10/09
GTGAnnual Report to shareholders
09/10/09
GTGInitial Director's Interest Notice
05/10/09
GTGDirector Appointment/Resignation
05/10/09
GTGPreliminary Final Report
28/08/09PRICE SENSITIVE
GTGAppendix 4C - quarterly
30/07/09PRICE SENSITIVE
GTGUS Patent Update
30/06/09
GTGExpiry of Options
11/06/09
GTGWithdrawal of German nullification action
10/06/09PRICE SENSITIVE
GTGImmunAid project update
09/06/09PRICE SENSITIVE
GTGAppendix 4C - quarterly
29/04/09PRICE SENSITIVE
GTGAppointment of new CEO
21/04/09
GTGExpiry of options
12/03/09
GTGHalf Yearly Report and Accounts
26/02/09PRICE SENSITIVE
GTGCancellation of options
02/02/09
GTGAppendix 4C - quarterly
29/01/09PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
3.9¢ 		Change
0.000(0.00%) 		Mkt cap ! $5.671M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
GTG (ASX) Chart

Top Stories

US election outcomes: Key economic and market takeaways

This week on Money @ Investing, Mitch Olarenshaw and I break down the recent U.S. presidential election, focusing on its effects on the stock market and the broader economic outlook. Here’s what we covered:1. Election results and policy insightsThe Republican Party&CloseCurlyQuote...
Power gets set for 1000-metre maiden drilling program in Brazil Power Minerals Ltd is planning a maiden drilling program to 1000 metres to test targets at its Nióbio project in Brazil
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Quit before you're fired: Russia bans uranium exports to USA, duplicating extant US ban Russia's ban of uranium exports to the USA came days before Biden allowed Ukraine use long-range missiles.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.